



LXREPAIR secures €1.1 million from seed funds for the development of its diagnostic kits in radiotherapy and chemotherapy

Grenoble, Sept 6th 2017 - LXREPAIR, a French company specialized in the development of disruptive technologies for DNA repair characterization, announces it has raised €1.1M from KREAXI, CEA-Investment, XPAND INVESTMENT Ltd of the KIS Group, Grenoble Angels, Savoie Mont-Blanc Angels, Gentiane Participation and individual investors.

The funds will be used to complete LXRepair clinical proofs of concepts in oncology, to obtain the CE marking of the kits and for international business development.

LXRepair's proprietary quantitative enzymatic assays offer a unique solution to identify predictive markers of response to anti-cancer therapies based on DNA repair measurements. DNA repair determine the response of patients to radiotherapy and chemotherapy (toxicity and resistance). LXRepair kits reveal the efficacy of DNA repair pathways from blood cells or tumor biopsy through series of fluorescent signals generated on a biochip.

By opposition to genetic approaches, the functional approach uncovers the real effectiveness of repair activities; multiplexing provides multiple information across the entire DNA repair network. These advantages make LXRepair tests more relevant and informative than other repair assays to identify DNA repair defects responsible for treatment failures.

The funding will enable LXRepair to complete the prospective clinical studies initiated to identify:

- Blood biomarkers of radiotoxicity (breast and prostate cancer)
- Tumor biomarkers of radio-chemo resistance (head and neck cancer)

Another major objective of LXRepair is to achieve the CE-IVD marking of its first kit in 2020 to predict the occurrence of radiotoxicity events.

"LXRepair is aiming for rapid development in the international medical diagnostics market. The fundraising will enable LXRepair to assess the clinical added value of its tests and to strengthen its patent portfolio. We want to establish our leading position for this new generation of diagnostic tests," says Sylvie Sauvaigo, CEO of LXRepair. "We are pleased to be supported by these funds with which we share many values."



About LXRepair

LXRepair is a CEA's spin-off, based in Grenoble, in the French Alps. It is supported by Bpi France and the CLARA oncology and cancer research cluster. LXRepair has established partnerships with Grenoble's Hospital, Hospices Civils de Lyon, Léon Bérard Center and Lucien Neuwirth Cancer Institute in Saint-Priest-en-Jarez.

Its first kit, Glyco-SPOT, a research use only kit, is industrialized and marketed by Bertin Pharma. The start-up contributes to the pre-clinical partnership between Grenoble's Hospital and the Roche institute to identify markers of responses to targeted therapies in metastatic melanoma and collaborates with pharmaceutical companies to identify clinical biomarkers for drug candidates' development.

Contact: Sylvie SAUVAIGO, CEO, sylvie.sauvaigo@lxrepair.com

About KREAXI

KREAXI was born from the merger between Rhône-Alpes Création and Banexi Ventures Partners, and is one of France's leading venture capital providers, raising over € 500 million in funds from public and private investors. Launched in 1989, KREAXI's regional activity (Kreaxi Region) has accompanied more than 260 companies by intervening in the capital of young Rhône-Alpes companies to finance their early development phases. With € 69 million in funds under management thanks to the support of the Rhône-Alpes Region, Bpifrance, regional banks and industrial groups, Kreaxi Region is in a central position in the financing of seed and creation stages. It manages a portfolio of about fifty holdings through its three funds (RAC I, RAC II and R2V), with an active team of nine people. www.kreaxi.com

Contact: Gwenaël HAMON, Director of Participations

About Supernova Invest

Created in 2017 by the experienced CEA Investissement team, CEA and Amundi, Supernova Invest is specialized in investing in breakthrough technology start-ups in life sciences, energy and industry (electronics, materials, instrumentation ...). In addition to the investments made with CEA Investissement and Amorçage Technologique Investissement, Supernova Invest raised two new funds mid-2017 and is now managing € 230 million from seed to venture capital. It has about fifty companies in its portfolio. The investment in LXRepair was made with CEA Investissement.

Contact: Celia HART, Partner, celia.hart@supernovainvest.com

About Gentiane Participations

This investment vehicle is Business Angels Investment Company. It is the 8th initiated by SAVOIE MONT-BLANC ANGELS an association dedicated to local investment, and a member of the national network France Angels. Its objective is to promote the development of territories and the creation of jobs by providing human support and financial resources to creators of innovative regional enterprises. More than 71 companies have been supported since 2008.

Contact: Laurent JAVAUDIN, Executive Office, laurent.javaudin@savoie-mont-blanc-angels.com

About Grenoble Angels

Created in 2005, at the instigation of Grenoble's Chamber of Commerce and Industry, **Grenoble Angels** contributes to local economic development with a durable willingness of accompanists and nearby investors. Awarded twice at France Angels Awards as the "Best Business Angels network", Grenoble Angels is one of the leading networks in France. Today, the association gathers over 140 members covering all sectors in the region. Since its creation, Grenoble Angels' members have invested directly € 21.42 million, and € 105.6 million with our co-investors in 109 companies financed and accompanied at 153 rounds. These companies have created more than 3,500 jobs.

Contact: Cheikhou DIEYE, grenobleangels@grenoble.cci.fr

